hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Abstract

Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.